

Fig. 1









Fig. 2a

*Type III Cer-1-TBDMS**C2 Cer-1-TBDMS**C6 Cer-1-TBDMS**C2 Cer-1-TBDPS*


664207-16962460

Fig. 2b




16562460

Fig. 2c




1-Acetate-3-one C6-Cer




4,5-Diol C6-Cer


Fig. 2d



N-Hexyl Sphingosine (or N-C8 Sphingosine)




N-C8 Sphingosine




N-C10 Sphingosine

Fig. 3




09429694-102793

Fig. 4



09429694-102799


Fig. 5



09429694-102799



Fig. 6



1562207-16362460

Fig. 7





Fig. 8



**Fig. 9A**

***In Vitro* Sensitivity of A549 to C6-Ceramide Derivatives After  
One Hour Drug Exposure**




Fig. 9B

*In Vitro* Sensitivity of A549 to C6-Ceramide Derivatives After  
Four Hour Drug Exposure





Fig. 9C

*In Vitro* Sensitivity of A549 to C6-Ceramide Derivatives After  
Eight Hour Drug Exposure



**Fig. 9D**

***In Vitro* Sensitivity of A549 to C6-Ceramide Derivatives After  
24 Hour Drug Exposure**




Fig. 9E

*In Vitro* Sensitivity of A549 to C6-Ceramide Derivatives After  
48 Hour Drug Exposure






Fig. 10

*In Vitro* Sensitivity of A549 to 1-Acetate C6-Ceramide at  
Different Exposure Times




Fig. 11




Fig. 12

*In Vitro* Sensitivity of A549 to 1-Isobutyrate C6-Ceramide at  
Different Exposure Times





Fig. 13

*In Vitro* Sensitivity of A549 to N-C8 Sphingosine at Different Exposure Times



Therapeutic efficacy of N-C6-Sphingosine  
against P-388/ADR tumor bearing mice

Fig. 14

